Evidence map›Paper›PMID 29340212›Full record

ArticleActa naturae

40 Years without Smallpox.

G A Shchelkunova, S N Shchelkunov

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05762523 phase1completednot on this map

An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC∆6 Vaccine) Based on Vaccinia Virus, in Volunteers Aged 18-40 Years

TypeinterventionalSponsorFederal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"Ran2019 to 2020Enrolled60ConditionsSmallpox, Monkeypox, Cowpox, Vaccinia Virus InfectionArmsVAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU, Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine
NCT05846243 phase2 / phase3completednot on this map

Double-blind, Comparative, Randomized, Placebo-controlled Study on Immunogenicity, Reactogenicity and Safety of Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VACΔ6 Vaccine) in Volunteers Aged 18-60 Years

TypeinterventionalSponsorFederal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"Ran2021 to 2022Enrolled334ConditionsSmallpox, Monkeypox, Cowpox, Vaccinia Virus InfectionArmsVAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine, Placebo (Sodium chloride bufus, 0.9%)
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Phylogeographical and evolutionary history ofLe infezioni in medicina · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

G A ShchelkunovaState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559 , Russia.
S N ShchelkunovState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559 , Russia.
State Research Center of Virology and Biotechnology VECTOR · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last case of natural smallpox was recorded in October, 1977. It took humanity almost 20 years to achieve that feat after the World Health Organization had approved the global smallpox eradication program. Vaccination against smallpox was abolished, and, during the past 40 years, the human population has managed to lose immunity not only to smallpox, but to other zoonotic orthopoxvirus infections as well. As a result, multiple outbreaks of orthopoxvirus infections in humans in several continents have been reported over the past decades. The threat of smallpox reemergence as a result of evolutionary transformations of these zoonotic orthopoxviruses exists. Modern techniques for the diagnostics, prevention, and therapy of smallpox and other orthopoxvirus infections are being developed today.

Indexed as

chemotherapeutic drugsDNA diagnosticsevolutionsmallpoxvaccinevariola (smallpox) virus

Identifiers

PMID29340212
PMCPMC5762823
OpenAlexW2908981482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.